{"organizations": [], "uuid": "79c78c50bf1aac22457c1d17c09ebb44e7bbeb56", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180206.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-allergan-announces-positive-phase/brief-allergan-announces-positive-phase-3-results-for-ubrogepant-idUSFWN1PW0MI", "country": "US", "domain_rank": 408, "title": "BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.426, "site_type": "news", "published": "2018-02-06T20:03:00.000+02:00", "replies_count": 0, "uuid": "79c78c50bf1aac22457c1d17c09ebb44e7bbeb56"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-allergan-announces-positive-phase/brief-allergan-announces-positive-phase-3-results-for-ubrogepant-idUSFWN1PW0MI", "ord_in_thread": 0, "title": "BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 6 (Reuters) - Allergan Plc:\n* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE\n* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES\n* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES\n* RESULTS OF SECOND PHASE 3 TRIAL, ACHIEVE II (UBR-MD-02), ARE EXPECTED IN 1ST HALF OF 2018\n* ALLERGAN - ANTICIPATES FILING NDA TO FDA FOR ACUTE MIGRAINE TREATMENT DRUG IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-06T20:03:00.000+02:00", "crawled": "2018-02-07T22:21:28.009+02:00", "highlightTitle": ""}